drugset
drugset / Trial / NCT03660748

Safety and Efficacy of MET-3 in Obese Human Subjects

NCT03660748 ↗

Phase 0 Completed 15 enrolled NuBiyota Glycemic Index Laboratories, Inc · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects

Timeline

Start
2018-10-01
Primary completion
2020-01-22
Completion
2020-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject MET-2 Other / unclassified — —

Indications

obesity disorder